Fractures vertébrales multiples à l’arrêt du denosumab: comment les éviter? [Multiple Vertebral Fractures after Denosumab Discontinuation: How to Avoid Them?]

Details

Ressource 1Request a copy Under indefinite embargo.
UNIL restricted access
State: Public
Version: author
License: Not specified
Serval ID
serval:BIB_AFA207F97FE4
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Fractures vertébrales multiples à l’arrêt du denosumab: comment les éviter? [Multiple Vertebral Fractures after Denosumab Discontinuation: How to Avoid Them?]
Journal
Praxis
Author(s)
Lamy O., Gonzalez Rodriguez E., Stoll D., Aubry-Rozier B., Livio F.
ISSN
1661-8157 (Print)
ISSN-L
1661-8157
Publication state
Published
Issued date
06/2018
Peer-reviewed
Oui
Volume
107
Number
12
Pages
649-654
Language
french
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Abstract
Multiple Vertebral Fractures after Denosumab Discontinuation: How to Avoid Them? Abstract. Denosumab is a monoclonal antibody raised against the RANK ligand that inhibits the maturation and activity of osteoclasts. It decreases bone resorption, increases bone density and reduces fracture risk. However, after its discontinuation, a significant rebound effect appears that lasts about two years. It results in increased markers of bone remodeling, a loss of bone density that may be greater than gain, and an increased risk of multiple vertebral fractures. These fractures occur at a frequency of 1 to 10 %. Due to this high risk, denosumab should be a second-line treatment limited to very specific indications. At denosumab discontinuation, in order to limit the rebound effect, the current recommendation is to prescribe a strong bisphosphonate (alendronate, zoledronate) and regularly monitor the bone resorption markers.
Keywords
Bisphosphonate, Denosumab, Rebound-Effekt, bisphosphonates, effet rebond, fractures vertébrales multiples, multiple Wirbelfrakturen, multiple vertebral fractures, rebound effect
Pubmed
Create date
15/06/2018 16:32
Last modification date
23/01/2020 6:19
Usage data